[
    [
        {
            "time": "2018-05-04",
            "original_text": "4 months after drug approval, Achaogen eyes fire sale",
            "features": {
                "keywords": [
                    "drug approval",
                    "Achaogen",
                    "fire sale"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "Pre-Market Most Active for Nov 5, 2018: AAPL, GE, ACRX, CHK, TEVA, GGB, AMD, QQQ, SQQQ, LYG, NVS, TQQQ",
            "features": {
                "keywords": [
                    "Pre-Market",
                    "Most Active",
                    "AAPL",
                    "GE",
                    "ACRX",
                    "TEVA",
                    "AMD"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "energy",
                    "healthcare",
                    "semiconductors"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 2,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "Novartis Issues R&D Update; Plans 60 Major Submissions From 2019 To 2021",
            "features": {
                "keywords": [
                    "Novartis",
                    "R&D Update",
                    "Major Submissions",
                    "2019 to 2021"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]